tertile 3 vs. tertile 1 2.14; 95 % CI 1.03, 4.47) and daidzein (HR for tertile 3 vs. tertile 1 2.05; 95 % CI 1.02, 4.11) were associated with an increased risk. A reduction in all-cause mortality was observed for elevated urinary concentrations of total enterolignans (HR for tertile 3 vs. tertile 1 0.65; 95 % CI 0.43, 0.96) and enterolactone (HR for tertile 3 vs. tertile 1 0.65; 95 % CI 0.44, 0.97). Conclusions Some urinary phytoestrogens were associated with cardiovascular and all-cause mortality in a representative sample of the US population. This is one of the first studies that used urinary phytoestrogens as biomarkers of their dietary intake to evaluate the effect of these bioactive compounds on the risk of death from cancer and cardiovascular disease.
Introduction
Cardiovascular disease and cancer are the leading causes of death in the USA [1] and many other developed countries throughout the world [2] . In the USA, 597,689 cardiovascular deaths and 574,743 cancer deaths occurred in 2010 [1] . On a global scale, cardiovascular disease was estimated to account for over 13 .2 million deaths in 2011 [2] , and total cancers claimed an estimated 8.2 million lives in 2012 [3] . To prevent the development of cancer and cardiovascular disease, it is necessary to identify their risk factors, particularly modifiable ones. One such modifiable factor is diet.
Phytoestrogens are a group of nonsteroidal plant metabolites. The principal classes of phytoestrogens include isoflavones and lignans. Isoflavones abound in soy products, legumes, and chick peas [4, 5] , and lignans primarily originate from seed oils, whole-grain cereals, and beans [6] . Isoflavones found in soy products include genistein, daidzein, and glycitein [7] , with these compounds arising after metabolism by the gut bacteria of the glycoside conjugates [8] . Daidzein can be further converted into two endogenous metabolites, equol and O-desmethylangolensin, with individual variation in the metabolism of daidzein in populations [9, 10] . Lignans commonly consumed by humans include enterolactone and enterodiol [11] . Differences in the biochemistry and food sources of individual phytoestrogens require investigation of both the overall effect of total phytoestrogens as a single family of bioactive compounds and the independent effect of each phytoestrogen in relation to disease risk.
A growing body of experimental evidence suggests that it is biologically plausible that phytoestrogen intake may modulate the risk of cancer and cardiovascular disease [12] [13] [14] [15] . Phytoestrogens can induce biological responses due to their structural similarity to 17β-estradiol when they are consumed in the diet [16] . The biological responses from phytoestrogens include estrogenic, anti-estrogenic, antioxidative, anti-viral, anti-bacterial, and anti-proliferative effects [11] . It has been found that the potential beneficial effect of phytoestrogens on some hormone-related cancers [17, 18] is mediated through their competitive binding to estrogen receptors [19, 20] . While estradiol exhibits an equal affinity to both α and β receptors (ERα and ERβ), phytoestrogens show a stronger affinity to ERβ [21] . For example, genistein has an approximately 30-fold greater affinity to the ERβ, and therefore may cause some clinical effects by selectively triggering this particular receptor [21] . Administration of phytoestrogens reduced serum testosterone levels in rats, an established risk factor for prostate cancer [12, 22] . It was also found that soy phytoestrogens reversed severe pulmonary hypertension and prevented heart failure in the same animals [13] .
Despite experimental evidence, few epidemiologic studies have examined the associations between phytoestrogen intake and cancer or cardiovascular mortality in western populations. Previous studies have focused on a few sites of cancer, mainly prostate [23, 24] and breast [25, 26] , yielding mixed results. Little is known about the association between phytoestrogen intake and cardiovascular disease [27] , although it is considered a promising area of research for cardiovascular disease prevention [28] . The consumption of soy products is lower in western countries than in Asian countries [18, 29] . However, several studies have reported a considerable between-person variation in phytoestrogen intake in western populations [30, 31] . This suggests that it is methodologically feasible to investigate the effect of phytoestrogens on health and disease in nonAsian countries. Several studies have shown that urinary concentrations of phytoestrogens are reliable, although modest, biomarker of phytoestrogen intake in both Asian and western populations [11, [32] [33] [34] [35] [36] . Significant positive correlations have been observed between usual intake of phytoestrogens and their urinary concentrations (e.g., r = 0.54 for isoflavones and r = 0.40 for lignans in a Canadian study [33] and r = 0.31 for isoflavones in a Hawaii study [34] . Correlations of similar magnitude have also been identified between soy intake and urinary phytoestrogens among Seventh-day Adventists (individuals with a wide range of soy intake) [35] and Minnesota residents [36] . To date, no epidemiologic studies have evaluated the associations between phytoestrogen intake and total cancer, cardiovascular, and all-cause mortality in a nationally representative sample of the US population. Therefore, the present study investigated this research question using data on urinary excretion of total and individual phytoestrogens as well as total cancer, cardiovascular, and all-cause mortality, previously collected from the continuous National Health and Nutrition Examination Survey (NHANES).
Subjects and methods

Study population
Data analyzed in this study were obtained from the NHANES for the years 1999-2004 and the NHANES linked public-use mortality file. The mortality file was created from a follow-up study of mortality that matched records from the individual years of the NHANES study with data in the National Death Index (NDI) through December 31, 2006 [37] . These data sources were selected because urinary phytoestrogen data for this six-year period only have been linked to mortality data in the NDI. NHANES is a cross-sectional study conducted by the Center for Disease Prevention and Control to assess the health and nutritional status of the general US population. Data collection and sampling procedures for NHANES have been described in detail elsewhere [38] . Sample weights were applied to the data through the calculation of a six-year weight variable according to the guidelines from the National Center for Health Statistics (NCHS) when combining two or more 2-year cycles of the continuous NHANES data to produce an unbiased national estimate.
From 1999 to 2004, 29,402 individuals enrolled in the NHANES completed the interview and health examination. As the objective of the present study was to investigate urinary phytoestrogens in relation to cancer, cardiovascular, and all-cause mortality, our analysis was confined to subjects who were ≥18 years and completed a 24-h dietary recall, reducing the sample size to 17,061. Urinary concentrations of phytoestrogens were measured among approximately one-third of total NHANES participants. Subsampling in NHANES was performed to reduce participant burden and facilitate scheduling and completion of examinations. All subjects in the subsample were randomly selected from the pool of total participants to obtain a nationally representative sample, with subsample weights calculated to account for probability of being selected into the subsample and additional non-response [39] . Excluding subjects without data on urinary phytoestrogens left the cohort with 5179 subjects, for whom 79 cancer deaths, 108 cardiovascular deaths, and 290 all-cause deaths were identified during a mean follow-up of approximately 5 years (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) . The de-identified data analyzed in the present study are freely available in public domains, and the approval for such data analysis by the Institutional Review Board of Indiana University was sought but determined not to be applicable.
Baseline data collection
NHANES participants were interviewed to collect data on age, sex, race (non-Hispanic white, non-Hispanic black, and other race including multiracial), marital status (married or living with partner, widowed, divorced or separated, and never married), and education level (less than high school, high school graduate or equivalent, and more than high school). Data were also collected on smoking status [never smokers (smoking 0 or <100 cigarettes in lifetime), former smokers (smoking ≥100 cigarettes in lifetime but not currently smoking), and current smokers], alcohol consumption (0 drink/week, <1 drink/week, and >1 drink/ week), and nutrient intake through a 24-h food recall. Body mass index (BMI) (kg/m 2 ) was calculated from height and weight measured during the medical examination portion of data collection.
Urinary phytoestrogen measurement
Phytoestrogen biomonitoring was accomplished by measuring urinary excretion of isoflavones (including daidzein, genistein, equol, and O-desmethylangolensin) and enterolignans (including enterodiol and enterolactone) using highperformance liquid chromatography (HPLC) with tandem mass spectrometric (MS/MS) detection [40] . The methods for the collection and analysis of urine samples for phytoestrogen concentrations have been described in detail elsewhere [41] . Briefly, subjects were assigned a date and time to report to one of the mobile examination centers to donate a urine sample. Spot urine specimens were collected the morning after a recommended fast, processed, stored at −20 °C, and then shipped to the Division of Environmental Health Laboratory Sciences at the NCHS for analysis. Urine samples were amended with stable isotope-labeled internal standards to improve method accuracy and precision, incubated with a de-conjugation enzyme to allow the quantification of individual phytoestrogens, extracted using solid phase extraction to remove interferences and improve sensitivity, and then analyzed using negative ion mode electrospray ionization HPLC-MS/MS, an assay with a high degree of specificity for each analyte [41] .
Mortality follow-up
International Classification of Diseases 10th Revision (ICD-10) codes were used in the selected databases that recorded cause-specific deaths ascertained during followup through December 31, 2006 [37] . The underlying causes of death were grouped according to the guidelines provided by the NCHS. The primary outcomes of the present study were cancer mortality (ICD-10 codes, C0-C97), cardiovascular mortality (ICD-10 codes, I00-I99), and all-cause mortality [42] .
Statistical analysis
The study population was divided into tertiles based on individuals' urinary concentrations of both total and each individual phytoestrogen to allow for an adequate number of subjects in each group. Total phytoestrogens were calculated by summing up all of the individual phytoestrogens, with a similar calculation completed for both total isoflavones and total enterolignans. Demographic, anthropometric, and lifestyle characteristics of subjects (including age, gender, race, BMI, education, smoking status, and alcohol intake) were compared by the tertiles of total urinary phytoestrogen (ng/ml) (tertile 1 4-414; tertile 2 415-1047; tertile 3 1048-112,457). Chi-square tests and analysis of variance were employed to compare differences in categorical and continuous variables among tertiles, respectively. Urinary concentrations of total and individual phytoestrogens were summarized by medians and interquartile ranges. Two-sided t tests were used to compare them between groups using log-transformed values to account for skewed distributions.
Cox proportional hazards regression was performed to calculate hazard ratios (HRs) and 95 % confidence intervals (CIs) for cancer, cardiovascular, and all-cause mortality in relation to urinary phytoestrogens. Deaths from other causes were treated as censored events in the analyses. The time variable for the Cox models was defined as the time period from the initial NHANES interview date to the date of death or December 31, 2006, whichever occurred first. The lowest tertile of urinary concentrations was the reference group to estimate HRs and 95 % CIs for the two upper tertiles. The multivariable models were adjusted for age, BMI, education, smoking status, total energy intake, sodium intake, and urinary creatinine. Urinary excretion of creatinine was entered into the models to account for urine dilution. Gender, race, marital status, and intake of fruits, vegetables, alcohol, fat, and calcium were examined as potential confounders but not included in the final models because they were not significantly associated with any of outcomes of interest in univariate models or did not substantively alter any risk estimates for all outcomes considered (<10 %). No interactions tested were found to be statistically significant or exhibited clear patterns, and thus, no interaction terms were included in the final model. Factors that were tested for their interactions with urinary phytoestrogens in relation to each of the three outcomes included age, gender, BMI, education, smoking status, total energy intake, and sodium intake. Linear trends across tertiles of phytoestrogen intake were tested by using the median in each tertile to create a continuous variable. A two-sided p value of <0.05 was considered statistically significant. SAS version 9.4 (Cary, NC) was used for all statistical analyses.
Results
Characteristics of study subjects are shown in Table 1 . Subjects were statistically significantly different across total phytoestrogen tertiles for gender, race, education, smoking status, and alcohol intake. Those in the highest tertile of urinary phytoestrogens were more likely to be male, non-Hispanic white, have more years of education, and be never smokers, but were less likely to be obese and nondrinkers. Table 2 shows differences in urinary concentrations of total and individual phytoestrogens between subjects who died of total cancer, cardiovascular disease, and all causes and those who remained alive during follow-up through the censor date (December 31, 2006). The median urinary concentrations of total phytoestrogens were lower in individuals who died of each of the three outcomes examined than respective individuals who were alive. Similarly, lower urinary concentrations of total enterolignans were observed for subjects who died of cardiovascular disease and all causes, and lower urinary levels of enterolactone were found for those who died of all causes. Conversely, the median urinary concentrations of total isoflavones and daidzein were higher among individuals who died of cardiovascular disease and all causes than those who remained alive. No significant differences in log-transformed means of total and individual phytoestrogens existed between subjects who did and did not die of each of the three outcomes of interest. Risk estimates for each of the three outcomes examined in relation to urinary excretion of total and individual phytoestrogens are presented in Table 3 . After adjustment for confounders, total phytoestrogens and each of individual phytoestrogens were not associated with a significantly altered risk of death from total cancers. A significantly increased risk of death from cardiovascular disease was found for higher urinary excretion of total isoflavones (HR for tertile 3 vs. tertile 1 2.14; 95 % CI 1.03, 4.47) and urinary daidzein (HR for tertile 3 vs. tertile 1 2.05; 95 % CI 1.02, 4.11). Conversely, higher total enterolignan excretion was significantly associated with a reduced risk of death from cardiovascular disease (HR for tertile 3 vs. tertile 1 0.48; 95 % CI 0.24, 0.97). Similarly, a significantly reduced all-cause mortality was found for higher urinary excretion of total enterolignans (HR for tertile 3 vs. tertile 1 0.65; 95 % CI 0.43, 0.96) and enterolactone (HR for tertile 3 vs. tertile 1 0.65; 95 % CI 0.44, 0.97). There was a suggestive threshold effect of urinary isoflavones and enterolignan on cardiovascular mortality and urinary isoflavones on allcause mortality.
To evaluate the possibility of reverse causality arising from preexisting chronic diseases, additional analyses were performed by removing individuals from the dataset who died within 2 years of enrollment into the study (n = 24 for total cancer and n = 43 for cardiovascular disease) [43, 44] . An increased risk of cancer death was observed for subjects in the second tertile of urinary total isoflavones (HR 2.62; 95 % CI 1.13, 6.10), but risk estimates for all other phytoestrogens remained insignificant. An increased risk of cardiovascular death persisted for subjects in the third tertile of urinary total isoflavones (HR 2.79; 95 % CI 1.10, 7.06), but an increased risk for individuals in the third tertile of urinary daidzein and a decreased risk for those in the third tertile of urinary total enterolignans (HR 0.39; 95 % CI 0.15, 1.00) were no longer significant. The reduced risk of all-cause mortality disappeared for subjects in the third tertile of urinary total enterolignans and the third tertile of urinary enterolactone.
Discussion
The present study investigated the associations between urinary phytoestrogens and cancer, cardiovascular, and all-cause mortality using data collected from a nationally representative sample of the US population. It was found that urinary concentrations of total enterolignans were significantly and inversely associated with cardiovascular and all-cause mortality, whereas urinary concentrations of total isoflavones and daidzein were significantly and positively associated with cardiovascular mortality. In addition, higher urinary concentrations of enterolactone were significantly associated with lower all-cause mortality.
Genistein is a main isoflavone present in soy products and has been one of the most widely investigated phytoestrogen metabolites. The present study did not show a significant association between urinary genistein and total cancer mortality, which was consistent with the results of several other studies in which genistein intake was not associated with the risk of different types of cancer [23, 24, 45] . Some studies have reported an inverse association between plasma concentrations of genistein and the risk of prostate and breast cancers [46, 47] . A few experimental studies revealed a protective effect of genistein on prostate cancer [48, 49] , whereas another experimental study reported an increased risk of colon cancer associated with genistein intake [50] . Collectively, all the studies discussed Adjusted for age, education, smoking status, body mass index, total energy intake, sodium intake, and urinary creatinine above suggest that dietary intake of individual isoflavones or lignans may exert different effects on individual types of cancer. Given the small number of total cancer deaths (n = 79) in the present study, it was not possible to examine cancer-specific associations with total and individual phytoestrogens, an intriguing question worthy of investigation in cohort studies with a larger number of cases of common cancers. Enterolactone is the main lignan metabolite in both urine and blood [11] . The urinary concentrations of this metabolite were found to reflect the habitual dietary intake of plant lignans [9] . As the precursors of enterolactone are detected in whole-grain products, legumes, seeds, fruits, and vegetables, the urinary concentrations of enterolactone are considered a biomarker for an overall healthy diet [23] . The present study showed low all-cause mortality associated with elevated urinary excretion of both total enterolignans and enterolactone. The consumption of lignan-rich foods has been associated with a decreased risk of breast and prostate cancers in some studies [18] and an increased risk of prostate cancer in other studies [51] . The present study did not show a significant association between urinary excretion of total or individual enterolignans and total cancer mortality. It has been found that enterolactone suppressed the proliferation and migration of prostate cancer cells [52] , which suggests that enterolactone intake may reduce the risk of prostate and some other cancers. The differential effects of enterolactone intake on the risk of different sites of cancer [18, 51] may account in part for the null results observed for this compound in relation to total cancer mortality in the present study. A significantly reduced risk of cardiovascular death associated with urinary excretion of total enterolignans was observed in the present study, which partially contributes to its inverse association with all-cause mortality.
Experimental and epidemiologic data are scarce examining the influence of intake of total and individual phytoestrogens on cardiovascular health and disease. One study showed that a lignan-rich diet was associated with elevated high-density lipoprotein concentrations and reduced triglyceride concentrations among US adults [53] . Increased serum concentrations of enterolactone have been associated with a reduced risk of acute coronary events and death from cardiovascular disease [54, 55] . The results from these previous studies are consistent with those of the present study. This protective effect of enterolactone on cardiovascular disease may be partially attributable to the inverse associations of its high urinary concentrations with inflammation biomarkers (C-reactive protein and white blood cell counts), obesity, and metabolic syndrome in human studies [56] [57] [58] . Animal and in vitro studies have offered additional mechanistic basis for the reduced cardiovascular mortality associated with elevated levels of urinary enterolactone [59] [60] [61] . Specifically, lignan complex [including secoisolariciresinol diglucoside (SDG)] isolated from flaxseed reduced the extent of hypercholesterolemic atherosclerosis and promoted its regression in rabbits [59, 60] . SDG induced an elevated expression of vascular endothelial growth factor (VEGF) in human coronary arteriolar endothelial cells [61] , and lack of VEGF led to ischemic cardiomyopathy in mice [62] .
Additionally, the present study showed an increased risk of cardiovascular death associated with urinary excretion of total isoflavones and daidzein. The results of previous studies on these associations are conflicting. A placebocontrolled, double-blinded trial of postmenopausal women supplemented with isoflavone soy protein showed no statistically significant effect on atherosclerosis progression [63] . Similarly, a meta-analysis of randomized controlled trials revealed that isoflavone supplementation did not improve endothelial function in postmenopausal women with high baseline flow-mediated dilation levels, but significant benefits were found for those with low baseline flow-mediated levels [64] . A cross-sectional study on middle-aged men in the USA reported that usual intake of isoflavones was not associated with a favorable cardiovascular risk profile [65] . A protective or null effect of isoflavones on cardiovascular disease that was observed in previous studies was inconsistent with a deleterious effect that was found in the present study. This difference might have arisen from two reasons: (1) Most previous studies were small dietary intervention trials among postmenopausal women; (2) in those studies, indicators of cardiovascular functions or biomarkers of cardiovascular lesions were examined; instead, the present study evaluated urinary excretion of total isoflavones and daidzein in relation to cardiovascular mortality among adult women and men of all ages. The potential biological mechanisms for an increased risk of cardiovascular disease associated with urinary levels of isoflavones remain elusive. However, genistein enhanced the gene expression of coagulation factors (prothrombin, factor VII, fibrinogen alpha, and fibrinogen beta) and C-reactive protein (all linked to cardiovascular disease risk) in ovariectomized rats [66] .
The present study has several advantages. Exposure to total and individual phytoestrogens was evaluated by measuring their urinary concentrations. Urinary excretion of phytoestrogens is free of recall bias inherent in food frequency questionnaires and is an integrated reflection of phytoestrogen intakes from all sources, including those that may be inadequately represented in food composition databases. For example, the most abundant sources of isoflavones in the diet are from foods containing soy products, such as tofu. However, soy additives are found in some processed foods [67] and certain isoflavones are naturally present in lower concentrations in other foods such as vegetables [68] , fruits, and nuts [69] . Another theoretical advantage of measuring urinary phytoestrogens is that this assay can also capture phytoestrogen metabolites (e.g., equol and O-desmethylangolensin) produced by intestinal bacteria [70] . It is critical to determine amounts of exposure to specific phytoestrogens because they differ in their levels of biological activity [18] . The US Department of Agriculture has a food composition database for isoflavones but not for lignans [71] , which does not allow us to calculate dietary intake of total phytoestrogens for participants in the NHANES. The present study is one of the first studies that used urinary phytoestrogens as biomarkers of their dietary intake to evaluate the effect of these bioactive compounds on the risk of death from cancer and cardiovascular disease. Most previous investigations of the effect of phytoestrogens on cancer risk were small case-control studies [51, 72] . Another strength of the present study is that the analysis prospectively evaluated associations between urinary phytoestrogens and all-cause and cause-specific mortality. The data used are based on a nationally representative sample with a relatively large between-person variation in urinary excretion of individual and total phytoestrogens.
Limitations of the present study need to be considered in the interpretation of obtained results. A small number of events for both cancer mortality and cardiovascular mortality did not allow us to perform a stratified analysis by type of cancer or cardiovascular disease. Future studies that incorporate a longer follow-up period may provide new insights into the etiology of cancers and cardiovascular diseases. Lack of adequate power may explain the null associations between urinary phytoestrogens (especially isoflavones) and cancer mortality. Spot urine was used to determine phytoestrogen concentrations, and the results of these measurements might be different from those using 24-h urine due to potential circadian rhythm. To adjust for urine dilution, phytoestrogen concentrations were normalized to urinary creatinine levels by including urinary creatinine in the Cox models, a commonly used method [32, 73] , because creatinine is excreted by glomerular filtration at a relatively constant rate [74] . There have been no studies examining the correlation between spot and 24-h urinary phytoestrogen concentrations. However, the concentrations of phytoestrogens, particularly individual isoflavones, in spot urine have been reported to be statistically significantly correlated with their concentrations measured in serum [75] . In addition, urinary biomarkers of phytoestrogens were measured only once, and a single measurement might not accurately reflect individuals' usual dietary intake due to within-person variation. To capture habitual intake of phytoestrogens, repeated measurements of urinary excretion of this family of chemicals may be necessary, but data on such repeated measurements are not available from NHANES due to feasibility limitations. Therefore, it is possible that some subjects might have been misclassified with regard to phytoestrogen intake because of a single measurement of urinary phytoestrogens and their modest correlations with dietary intake.
Significant associations of urinary excretion of daidzein and total enterolignans with cardiovascular and/or all-cause mortality disappeared after excluding subjects who died within 2 years of enrollment, which suggests that these associations are reported in Table 3 may be partially ascribed to reverse causality due to the presence of subclinical disease. As NHANES did not exclude individuals with diseases at baseline, some individuals with clinical and/or subclinical disease might have been included in this study. Exact biological or physiological functions of most individual phytoestrogens remain to be elucidated. Therefore, caution needs to be exercised when interpreting their observed effects on disease risk in epidemiologic studies. Mortality data were analyzed in the present study. Therefore, obtained results may be less relevant to the etiology of total cancer and cardiovascular diseases than, and could not be directly compared with, those from analysis of incidence data because mortality of these two outcomes may be influenced by differences in access to and quality of medical treatment among study subjects. No significant differences existed in sex, race, BMI, and smoking status between the participants who donated a urine sample and those who did not. Although the former were a little younger, attained a somewhat higher level of education, and were more likely to drink alcohol than the latter, the differences in these variables were small and the impact was considered inconsequential.
In summary, the present study suggests that higher urinary concentrations of total enterolignans were associated with a reduced risk of death from cardiovascular disease. Similarly, elevated urinary concentrations of both total enterolignans and enterolactone were associated with low all-cause mortality. Conversely, higher urinary concentrations of total isoflavones and daidzein were significantly associated with an increased risk of death from cardiovascular disease and all causes. The observed results of total phytoestrogens need to be interpreted with caution due to potential differences in the physiological functions of individual phytoestrogens. It is important and timely to further investigate the associations of phytoestrogen intake, its biomarkers, and metabolic polymorphisms with the risk of total cancer, specific cancers, and cardiovascular disease in large prospective cohort studies as data generated from such studies may offer innovative avenues for the prevention of these major diseases among people across the world.
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